Physician profile
John Charles Stapleton
NPI 1710348354
$2,457.67
in general payments reported to CMS, 2019-2025
16 companies · $865 in 2025
The $865 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $29.07 · 2022: $277 · 2023: $455 · 2024: $832 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $791.86 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $334.65 | 2022-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $291.22 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $270.89 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $231.05 | 2023-2025 | |
| Lilly USA, LLC | $145.77 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $83.95 | 2022-2025 | Trintellix |
| Lundbeck LLC | $76.93 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $53.05 | 2021-2025 | Gardasil 9, Capvaxive |
| Amgen INC. | $50.51 | 2023-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $29.04 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $28.97 | 2024 | Veozah |
| Exact Sciences Corporation | $20.45 | 2025 | The Cologuard Plus Collection Kit |
| Ironshore Pharmaceuticals INC. | $17.52 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.45 | 2025 | Caplyta |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $14.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stapleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.